TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant
- 1 August 2019
- journal article
- research article
- Published by Elsevier in Annals of Diagnostic Pathology
- Vol. 41, 38-42
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Molecular pathogenesis of mantle cell lymphomaJournal of Clinical Investigation, 2012
- Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphomaBlood, 2012
- The complex landscape of genetic alterations in mantle cell lymphomaSeminars in Cancer Biology, 2011
- Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosisHaematologica, 2011
- Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic eraBlood, 2011
- Outcome of Deferred Initial Therapy in Mantle-Cell LymphomaJournal of Clinical Oncology, 2009
- Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeuticsNature Reviews Cancer, 2007
- Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL NetworkBlood, 2005
- Immunoglobulin heavy chain genes somatic hypermutations and chromosome 11q22‐23 deletion in classic mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer ResearchBritish Journal of Haematology, 2004
- Cytogenetic Findings in Mantle Cell LymphomaAmerican Journal of Clinical Pathology, 2001